Abstract 2885
Background
Cancer-associated thrombosis (CAT) is a well–known complication of cancer, especially pancreatic cancer. One possible cause of CAT is secretion of tissue factor (TF)-positive extracellular vesicles from cancer cells. The previous cohort of Western countries showed that patients (pts) with a high level of TF tended to develop CAT with 20–40% incidence in pancreatic cancer. This prospective cohort study aimed to assess the efficacy of TF level for predicting the incidence of CAT in Japanese pts with pancreatic cancer.
Methods
We registered consented 197 pts from June 2013 to November 2016, who had pathologically confirmed pancreatic cancer and no history of treatment for the current disease. Plasma samples were collected from pts at the time of registration, 3, 6, and 12 months after. The TF level was evaluated using the Quantikine® ELISA kit (R&D systems) as we found that TF levels in multiple cancer cell lines evaluated using this kit correlated well with those analyzed by western blotting experiments. We estimated the positive (PPV) and negative predictive values (NPV) for the incidence of CAT by using obtained plasma TF levels (cutoff value: 100 pg/ml) and D-dimer levels (cutoff value: 1.2 μg/ml).
Results
Of all the patients, 189 patients were with unresectable disease. The median of the initial level of TF for these pts was 47.8 pg/ml (range: 0.0—318.7). The incidence of CAT was observed in 13 pts (6.6%) at the median follow-up time of 325 days. The median TF level at the time of registration was 148.5 pg/ml in CAT+ group and 53.5 pg/ml in CAT- group with a p–value of < 0.0001. PPV and NPV estimated by TF levels at the time of registration were 23.1% and 94.6%, and by the D-dimer levels were 7.2% and 92.4%, respectively. In pts with a D-dimer level >1.2 µg/ml, NPV by TF < 100 pg/ml was 95%. Similar results were obtained when TF levels of 3 months before the onset of CAT were used.
Conclusions
Present study revealed that the incidence of CAT in Japanese pts was lower than that of Western countries. It was also found that TF levels alone could not predict CAT observed in Japanese pts with pancreatic cancer: however, TF levels were found to contribute to high NPV even in pts with a high level of D–dimer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3902 - The efficacy of preoperative breast cancer chemotherapy without anti-HER2-targeted treatment – single center experience in setting of no reimbursement in Poland (2011-2015)
Presenter: Agnieszka Badora-Rybicka
Session: Poster Display session 2
Resources:
Abstract
4733 - A Multicentre, International Neoadjuvant (NA), Randomized, Double-blind Phase III Trial comparing FULVESTRANT to a combination of FULVESTRANT and PALBOCICLIB in patients with operable Luminal Breast Cancer (SAFIA Trial)
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 2
Resources:
Abstract
5227 - Outcome of Non-metastatic Male Breast Cancer: 222 patients
Presenter: Ulku Yalcintas Arslan
Session: Poster Display session 2
Resources:
Abstract
5943 - Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, Her2 positive breast cancer in a limited resources setting: ML25232 study final results
Presenter: Samir Beslija
Session: Poster Display session 2
Resources:
Abstract
1725 - Final results of scalp cooling for hair preservation: A single- institution prospective study.
Presenter: Dario Loparco
Session: Poster Display session 2
Resources:
Abstract
3713 - Adjuvant Systemic Therapy in Women with Early Breast Cancer and Intermediate Prosigna ROR Scores: Is Chemotherapy Use Declining? Evidence From a Large Practice
Presenter: Lowell Hart
Session: Poster Display session 2
Resources:
Abstract
818 - Management of early breast cancer in women over 90: A 10 year experience
Presenter: Emily Coffey
Session: Poster Display session 2
Resources:
Abstract
1141 - Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early- stage breast cancer.
Presenter: Daniel Reinhorn
Session: Poster Display session 2
Resources:
Abstract
2277 - Hepatitis B screening and incidence of flare among non-metastatic breast cancer patients treated with anthracyclines
Presenter: Zewen Zhang
Session: Poster Display session 2
Resources:
Abstract
2781 - Effect of denosumab on low bone mineral density in postmenopausal Japanese early breast cancer patients receiving aromatase nhibitors : 36-month results
Presenter: Koichi Sakaguchi
Session: Poster Display session 2
Resources:
Abstract